Company Overview - Tianzhihang Medical Technology Co., Ltd. is a leading enterprise in the orthopedic surgical robot industry in China, focusing on the research, production, sales, and service of orthopedic surgical navigation robots [1] - The company is recognized as one of the top 10 robotics companies in China and serves as a key unit for national and local joint engineering research centers for medical robots [1] Financial Performance - For the third quarter of 2024, the company reported a revenue of 92.12 million yuan, representing a year-on-year decrease of 31.08% [1] - The net profit for the same period was -76,172,852.88 yuan, showing a year-on-year decline of 5.68% [1] - The gross profit margin stood at 67.45% [1] Shareholder Information - As of September 30, 2024, Tianzhihang had 16,018 shareholders, an increase of 406 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Market Valuation - The company's latest closing price was 11.63 yuan, down by 2.19%, with a price-to-book ratio of 4.46 and a total market capitalization of 5.265 billion yuan [1] - Compared to industry averages, Tianzhihang's price-to-earnings (P/E) ratio (TTM) is -42.76, while the industry average is 46.75 [2]

Group 1 - The core viewpoint of the articles highlights Tianzhihang's position as a leading enterprise in the orthopedic surgical robot industry in China, with a focus on research, production, sales, and services of surgical navigation robots [1][2] - As of the latest quarterly report for Q3 2024, the company reported a revenue of 92.12 million yuan, reflecting a year-on-year decrease of 31.08%, and a net loss of approximately 76.17 million yuan, with a slight year-on-year decline of 5.68% [1] - The company's gross profit margin stands at 67.45%, indicating a relatively high profitability despite the decline in revenue [1] Group 2 - Tianzhihang's current stock price is 11.81 yuan, with a market capitalization of 5.346 billion yuan and a price-to-book ratio of 4.53 [1] - The company is among the top 10 members of the Chinese robotics industry and serves as a key research center for medical robotics [1] - The average price-to-earnings (PE) ratio for the industry is 47.69, while Tianzhihang's PE ratio is significantly negative at -43.42, indicating potential challenges in profitability compared to industry peers [2]

Group 1 - The core viewpoint of the articles highlights Tianzhihang's current market performance, including a stock price drop and financial metrics indicating challenges in revenue and profit [1][2] - Tianzhihang's latest closing price is 11.5 yuan, reflecting a decrease of 3.93%, with a market-to-book ratio of 4.41 and a total market capitalization of 5.206 billion yuan [1] - As of September 30, 2024, Tianzhihang has 16,018 shareholders, an increase of 406 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tianzhihang is recognized as a leading enterprise in the orthopedic surgical robot industry in China, focusing on the research, production, sales, and service of orthopedic surgical navigation robots [1] - The company is part of the top 10 robotics firms in China and serves as a key unit for national and local joint engineering research centers in medical robotics [1] - The latest financial report for Q3 2024 shows a revenue of 92.121 million yuan, a year-on-year decrease of 31.08%, and a net loss of approximately 76.173 million yuan, with a gross profit margin of 67.45% [1]

Core Insights - Tianzhihang Medical Technology Co., Ltd. is a leading enterprise in the orthopedic surgical robot industry in China, focusing on the research, production, sales, and service of orthopedic surgical navigation robots [1] - As of the latest quarterly report for Q3 2024, the company reported a revenue of 92.12 million yuan, a year-on-year decrease of 31.08%, and a net profit loss of approximately 76.17 million yuan, a year-on-year decline of 5.68% [1] - The company's gross profit margin stands at 67.45%, indicating a strong profitability despite the revenue decline [1] Company Overview - Tianzhihang is recognized as one of the top 10 robotics companies in China and serves as a key research center for national and local engineering in medical robotics [1] - The company has 33 institutional investors holding a total of 2.435 million shares, with a market value of 2.4 million yuan [1] Financial Metrics - The company's current price-to-earnings (P/E) ratio is -42.43, indicating negative earnings, while the industry average P/E is 46.15 [2] - The price-to-book (P/B) ratio is 4.43, with a total market capitalization of 5.224 billion yuan [2] - Comparatively, the industry median P/B ratio is 2.31, suggesting that Tianzhihang is valued higher than the industry average [2]

法定代表人：张送根 证券代码：688277 证券简称：天智航 公告编号：2025-016 北京天智航医疗科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 2 日召开 2025 年第一次临时股东大会，审议通过了《关于变更公司住所及修订< 公司章程>的议案》，具体内容详见公司于 2025 年 4 月 3 日在上海证券交易所网 站（www.sse.com.cn）披露的《2025 年第一次临时股东大会决议公告》。 公司已于 2025 年 4 月 9 日完成上述事项的工商变更登记和备案手续，并收 到了北京市海淀区市场监督管理局换发的《营业执照》，具体信息如下： 统一社会信用代码：911101085636544700 名称：北京天智航医疗科技股份有限公司 类型：股份有限公司（上市、自然人投资或控股） 注册资本：44,939.1939 万元 成立日期：2010 年 10 月 22 日 住所：北京市海淀区建 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ●本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为3,276,650股（其中首次授予部 分2,543,570股，预留授予部分733,080股）。 本次股票上市流通总数为3,276,650股。 ●本次股票上市流通日期为2025年4月11日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分公司有关业务规则的规定， 北京天智航医疗科技股份有限公司（以下简称"本公司"、"公司"）于2025年4月8日收到中国证券登记结 算有限责任公司上海分公司出具的《证券变更登记证明》，公司完成了2023年限制性股票激励计划首次 及预留授予部分第一个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 1、2023年4月25日，公司召开第五届董事会第二十一次会议，审议通过了《关于公司〈2023年限制性股 票激励计划（草案）〉及其摘要的议案》《关于公司〈2023年限制性股票激励计划实施考核管理办法〉 的议案》《关于提请股东大会授权董事会办理公司2023年限制性股票激励计划有关事项的议案》等相关 议案。公司独立董事就 ...

证券代码：688277 证券简称：天智航 公告编号：2025-015 北京天智航医疗科技股份有限公司 2023 年限制性股票激励计划首次及预留授予部分 第一个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 3,276,650 股（其中首次授予部分 2,543,570 股，预留授予部分 733,080 股）。 本次股票上市流通总数为 3,276,650 股。 本次股票上市流通日期为 2025 年 4 月 11 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分公 司有关业务规则的规定，北京天智航医疗科技股份有限公司（以下简称"本公司"、 "公司"）于 2025 年 4 月 8 日收到中国证券登记结算有限责任公司上海分公司出 具的《证券变更登记证明》，公司完成了 2023 年限制性股票激励计划首次及预留 授予部分第一个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及 ...

最新一期业绩显示，2024年三季报，公司实现营业收入9212.10万元，同比-31.08%；净利 润-76172852.88元，同比-5.68%，销售毛利率67.45%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11天智航-46.39-46.394.8457.12亿行业平均 46.4850.124.81107.65亿行业中值31.9631.102.5148.33亿1硕世生物-1929.78-1929.781.2139.87亿2诺唯 赞-572.21-572.212.4797.29亿3博晖创新-307.63-189.403.3947.22亿4康泰医学-301.2235.343.0858.58亿5华 大基因-212.46232.392.20215.89亿6奥精医疗-120.00-120.001.5321.74亿7睿昂基因-84.92-84.921.3212.28亿 8热景生物-55.35-55.353.0499.21亿9中红医疗-54.71-37.220.8748.71亿10华大智造-54.09-54.094.06324.05亿 来源：金融界 4月3日，天智航今日收盘12.71元，下跌1.32%，最 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达律师事务所 关于北京天智航医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 康达股会字【2025】第 0064 号 致：北京天智航医疗科技股份有限公司 北京市康达律师事务所（以下简称"本所"）接受北京天智航医疗科技股 份有限公司（以下简称"公司"）的委托，指派本所律师对公司 2025 年第一次 临时股东大会（以下简称"本次会议"）的合法性进行见证并出具《北京市康达 律师事务所关于北京天智航医疗科技股份有限公司 2025 年第一次临时股 ...